Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accounts Payables (2019 - 2025)

Historic Accounts Payables for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $18.7 million.

  • BridgeBio Pharma's Accounts Payables rose 3995.36% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 3995.36%. This contributed to the annual value of $9.6 million for FY2024, which is 973.25% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Accounts Payables stood at $18.7 million, which was up 3995.36% from $26.1 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Accounts Payables high stood at $27.5 million for Q1 2025, and its period low was $3.9 million during Q2 2023.
  • Its 5-year average for Accounts Payables is $12.6 million, with a median of $10.7 million in 2023.
  • In the last 5 years, BridgeBio Pharma's Accounts Payables tumbled by 6062.07% in 2022 and then skyrocketed by 48217.01% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Accounts Payables (Quarter) stood at $11.9 million in 2021, then dropped by 2.74% to $11.6 million in 2022, then decreased by 7.81% to $10.7 million in 2023, then decreased by 9.73% to $9.6 million in 2024, then soared by 94.45% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $26.1 million for Q2 2025, and $27.5 million during Q1 2025.